76Bio

Targeted Protein Degraders

76Bio, founded in 2020, is developing therapies that target unnecessary proteins for degradation in treatment of various life-threatening diseases. The team has backgrounds in immunology, oncology, biology, and genetics. CEO, Christopher Wilfong, previously co-founded and held leadership positions at other Two River companies, including Kite Pharma, Kronos Bio, and Neogene Therapeutics. 76Bio’s R&D headquarters is located in Boston, MA.